Not really, but in the (very) recent 10K, it's interesting to note the different language for the DYAX and ABGX programs. The implication is that it will be easy to leave the ABGX compounds to ABGX, but backing away from the DYAX deal might be more complicated:
sec.gov
In April 2002, we entered into an exclusive collaboration agreement with Abgenix to discover, develop and commercialize fully-human monoclonal antibodies against two selected antigens from our portfolio of membrane-bound serine proteases. Under the terms of the collaboration, Abgenix will use its human antibody technologies to generate and select antibodies against the Corvas targets. Both companies will have the right to co-develop and commercialize, or, if co-development is not elected, to solely develop and commercialize any antibody products discovered during the collaboration. Both companies will share equally in the product development costs and any profits from sales of products successfully commercialized from any co-development efforts.
-6-
<PAGE>
In September 2001, we entered into a strategic alliance with Dyax to discover, develop and commercialize antibody, small protein and peptide inhibitors for two targets that we isolated and characterized. Under the terms of this agreement, both companies will jointly develop any inhibitory agents that may be identified and will share commercialization rights and profits, if any, from any marketed products. We believe that such joint development efforts may help maximize the potential of our serine protease approach to combat cancer by enabling a more rapid validation of these potential cancer targets and by providing additional sources of potential lead drug candidates to advance into clinical testing.
Clearly DNDN isn't a done deal yet. The 'strategy' section addresses this in detail -
"In the event we continue as a stand alone company..." |
